Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson Sells 11,447 Shares

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $7.95, for a total transaction of $91,003.65. Following the completion of the transaction, the director now directly owns 7,218,414 shares of the company’s stock, valued at $57,386,391.30. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, April 16th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.66, for a total transaction of $87,684.02.
• On Tuesday, April 2nd, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $8.82, for a total transaction of $100,962.54.
• On Tuesday, March 19th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $10.79, for a total transaction of $216,382.66.
• On Tuesday, March 5th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $12.06, for a total transaction of $241,851.24.
• On Tuesday, February 20th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $12.32, for a total transaction of $247,065.28.
• On Tuesday, February 6th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $9.30, for a total transaction of $106,457.10.

Recursion Pharmaceuticals Stock Performance

Shares of Recursion Pharmaceuticals stock traded up $0.45 during midday trading on Thursday, reaching $8.79. 3,792,689 shares of the company’s stock traded hands, compared to its average volume of 6,395,401. The company has a market cap of $2.06 billion, a price-to-earnings ratio of -5.67 and a beta of 0.85. The company’s 50 day simple moving average is $10.10 and its 200 day simple moving average is $9.16. Recursion Pharmaceuticals, Inc. has a 52 week low of $4.55 and a 52 week high of $16.75.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Tuesday, February 27th. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.06. The business had revenue of $10.89 million for the quarter, compared to the consensus estimate of $12.37 million. Recursion Pharmaceuticals had a negative net margin of 735.99% and a negative return on equity of 72.88%. As a group, equities research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.63 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Benjamin F. Edwards & Company Inc. acquired a new position in Recursion Pharmaceuticals in the 1st quarter valued at $26,000. National Bank of Canada FI grew its stake in Recursion Pharmaceuticals by 90.9% in the 4th quarter. National Bank of Canada FI now owns 3,150 shares of the company’s stock valued at $31,000 after buying an additional 1,500 shares during the last quarter. First Horizon Advisors Inc. acquired a new position in Recursion Pharmaceuticals in the 4th quarter valued at $47,000. China Universal Asset Management Co. Ltd. grew its stake in Recursion Pharmaceuticals by 116.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,237 shares of the company’s stock valued at $40,000 after buying an additional 2,817 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its stake in Recursion Pharmaceuticals by 25.4% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 10,123 shares of the company’s stock valued at $77,000 after buying an additional 2,050 shares during the last quarter. Institutional investors own 89.06% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on RXRX shares. KeyCorp upped their target price on shares of Recursion Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research report on Monday, March 4th. Needham & Company LLC reiterated a “buy” rating and issued a $17.00 price objective on shares of Recursion Pharmaceuticals in a report on Tuesday, April 9th. Finally, TD Cowen initiated coverage on shares of Recursion Pharmaceuticals in a report on Friday, January 26th. They issued a “market perform” rating for the company. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $12.75.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.